Media Thread, page-14635

I agree, you only have to look at Blincyto history of approval as another example. I have to say, AMGEN did a great job in getting this drug approved so quickly.

Development timeline for Blincyto

The drug (originally known as MT103) was developed by a German-American company Micromet, Inc. in cooperation with Lonza; In 2012, Micromet was purchased by Amgen, which furthered the drug's clinical trials.

	Date	Article
1	Jun 14, 2024	ApprovalFDA Approves Blincyto (blinatumomab) in CD19-Positive Philadelphia Chromosome-Negative B-ALL in the Consolidation Phase
2	Jun 21, 2023	ApprovalFDA Grants Full Approval for Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
3	Mar 29, 2018	ApprovalFDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
4	Jul 11, 2017	ApprovalFDA Grants Full Approval for Blincyto (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children
5	Sep 1, 2016	ApprovalFDA Approves Blincyto (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
6	Dec 3, 2014	ApprovalFDA Approves Blincyto (blinatumomab) for Precursor B-Cell Acute Lymphoblastic Leukemia
7	Oct 9, 2014	Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia
8	Sep 22, 2014	Amgen Submits BLA for Investigational BiTE® Immunotherapy Blinatumomab
9	Jul 1, 2014	Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE Antibody Blinatumomab In Acute Lymphoblastic Leukemia

Source: https://www.drugs.com/history/blincyto.html and https://en.wikipedia.org/wiki/Blinatumomab

Cost
When blinatumomab was approved, Amgen announced that the price for the drug would be US$178,000 per year, which made it the most expensive cancer drug on the market. Merck's pembrolizumab was priced at US$150,000 per year when it launched (in September 2014).[15] At the time of initial approval, only about 1,000 patients in the US had an indication for blinatumomab.